MIRA Pharmaceuticals’ Ketamir-2 Outperforms FDA-Approved Gabapentin by 60% in Reducing Chemotherapy-Induced Pain
    MIRA Pharmaceuticals’ Ketamir-2 Outperforms FDA-Approved Gabapentin by 60% in Reducing Chemotherapy-Induced Pain
    PRISM Biotech

    October 28, 2024 - by Ashlee Vogenthaler

    MIRA Pharmaceuticals’ Ketamir-2 Outperforms FDA-Approved Gabapentin by 60% in Reducing Chemotherapy-Induced Pain

    28 October 2024

    New York, October 28, 2024 - PRISM MarketView - Shares of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) rose 14% following the announcement of new preclinical data showing that Ketamir-2, an innovative oral ketamine analog, demonstrated 60% greater efficacy than gabapentin, the current FDA-approved standard, in reducing chemotherapy-induced neuropathic pain. These findings will be presented at the Pain Therapeutics Summit in Boston.

    Mira Pharmaceuticals - Prism MarketView

    Mira Pharmaceuticals Developing the next-generation FDA-approved novel synthetic THC analog MIRA1a is being developed to treat anxiety and cognitive decline i

    Read More

    Key Highlights:
    • In a preclinical model, Ketamir-2 achieved near-complete normalization of pain sensitivity in mice with chemotherapy-induced neuropathy, significantly outperforming gabapentin.
    • Positive results position Ketamir-2 as a candidate for FDA’s breakthrough therapy, fast track, or priority review designations, potentially accelerating its pathway to market.
    • MIRA plans to submit an Investigational New Drug (IND) application by the end of 2024, with Phase I clinical trials expected to begin in early 2025. Parallel Phase II trials targeting multiple neuropathic pain conditions are also under consideration.
    • Ketamir-2 is under evaluation for other indications, including diabetic neuropathy and post-traumatic stress disorder (PTSD), with preclinical studies underway.
    The Pain Therapeutics Summit takes place in Boston on October 28-29, 2024
    To see this content properly accept cookies.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    To see this content properly accept cookies.
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.